Effects of cyclosporine on glucose metabolism

Lisa S. Dresner, Dana Andersen, Kim U. Kahng, Imtiaz A. Munshi, Richard B. Wait

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Cyclosporine may have deleterious effects on glucose metabolism. This study was designed to characterize more precisely cyclosporine-induced alterations in glucose homeostasis in a large animal model with hyperglycemic and euglycemic clamp studies in addition to simple bolus glucose (IVGTT) and insulin (IVITT) tolerance tests. In experiment 1, IVGTTs and hyperglycemic clamp studies were performed in eight ewes before and after 4 weeks of cyclosporine treatment. Studies were repeated 4 weeks after cessation of therapy. In experiment 2, IVITTs and euglycemic clamp studies were performed in seven ewes before and after 4 weeks of cyclosporine treatment. Fasting glucose and insulin levels were not affected by cyclosporine treatment. In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37% decrease in net glucose disposal (p <0.001) and a 39% decrease in plateau plasma insulin levels (p <0.05). In experiment 2 cyclosporine had no effect on IVITTs. Plateau insulin values in euglycemic clamp studies were lowered by 27% (p <0.05) after cyclosporine treatment. In addition, the metabolic clearance rate of insulin was increased by 25% (p <0.05), and the steady-state insulin clearance rate was increased by 16% (p <0.003). Measurements of insulin sensitivity were unchanged by cyclosporine. These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalSurgery
Volume106
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

Cyclosporine
Glucose
Insulin
Glucose Clamp Technique
Insulin Resistance
Metabolic Clearance Rate
Hyperglycemia
Fasting
Homeostasis
Animal Models

ASJC Scopus subject areas

  • Surgery

Cite this

Dresner, L. S., Andersen, D., Kahng, K. U., Munshi, I. A., & Wait, R. B. (1989). Effects of cyclosporine on glucose metabolism. Surgery, 106(2), 163-170.

Effects of cyclosporine on glucose metabolism. / Dresner, Lisa S.; Andersen, Dana; Kahng, Kim U.; Munshi, Imtiaz A.; Wait, Richard B.

In: Surgery, Vol. 106, No. 2, 1989, p. 163-170.

Research output: Contribution to journalArticle

Dresner, LS, Andersen, D, Kahng, KU, Munshi, IA & Wait, RB 1989, 'Effects of cyclosporine on glucose metabolism', Surgery, vol. 106, no. 2, pp. 163-170.
Dresner LS, Andersen D, Kahng KU, Munshi IA, Wait RB. Effects of cyclosporine on glucose metabolism. Surgery. 1989;106(2):163-170.
Dresner, Lisa S. ; Andersen, Dana ; Kahng, Kim U. ; Munshi, Imtiaz A. ; Wait, Richard B. / Effects of cyclosporine on glucose metabolism. In: Surgery. 1989 ; Vol. 106, No. 2. pp. 163-170.
@article{b79e2473c4a5403d8b0b1412d894599e,
title = "Effects of cyclosporine on glucose metabolism",
abstract = "Cyclosporine may have deleterious effects on glucose metabolism. This study was designed to characterize more precisely cyclosporine-induced alterations in glucose homeostasis in a large animal model with hyperglycemic and euglycemic clamp studies in addition to simple bolus glucose (IVGTT) and insulin (IVITT) tolerance tests. In experiment 1, IVGTTs and hyperglycemic clamp studies were performed in eight ewes before and after 4 weeks of cyclosporine treatment. Studies were repeated 4 weeks after cessation of therapy. In experiment 2, IVITTs and euglycemic clamp studies were performed in seven ewes before and after 4 weeks of cyclosporine treatment. Fasting glucose and insulin levels were not affected by cyclosporine treatment. In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37{\%} decrease in net glucose disposal (p <0.001) and a 39{\%} decrease in plateau plasma insulin levels (p <0.05). In experiment 2 cyclosporine had no effect on IVITTs. Plateau insulin values in euglycemic clamp studies were lowered by 27{\%} (p <0.05) after cyclosporine treatment. In addition, the metabolic clearance rate of insulin was increased by 25{\%} (p <0.05), and the steady-state insulin clearance rate was increased by 16{\%} (p <0.003). Measurements of insulin sensitivity were unchanged by cyclosporine. These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.",
author = "Dresner, {Lisa S.} and Dana Andersen and Kahng, {Kim U.} and Munshi, {Imtiaz A.} and Wait, {Richard B.}",
year = "1989",
language = "English (US)",
volume = "106",
pages = "163--170",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of cyclosporine on glucose metabolism

AU - Dresner, Lisa S.

AU - Andersen, Dana

AU - Kahng, Kim U.

AU - Munshi, Imtiaz A.

AU - Wait, Richard B.

PY - 1989

Y1 - 1989

N2 - Cyclosporine may have deleterious effects on glucose metabolism. This study was designed to characterize more precisely cyclosporine-induced alterations in glucose homeostasis in a large animal model with hyperglycemic and euglycemic clamp studies in addition to simple bolus glucose (IVGTT) and insulin (IVITT) tolerance tests. In experiment 1, IVGTTs and hyperglycemic clamp studies were performed in eight ewes before and after 4 weeks of cyclosporine treatment. Studies were repeated 4 weeks after cessation of therapy. In experiment 2, IVITTs and euglycemic clamp studies were performed in seven ewes before and after 4 weeks of cyclosporine treatment. Fasting glucose and insulin levels were not affected by cyclosporine treatment. In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37% decrease in net glucose disposal (p <0.001) and a 39% decrease in plateau plasma insulin levels (p <0.05). In experiment 2 cyclosporine had no effect on IVITTs. Plateau insulin values in euglycemic clamp studies were lowered by 27% (p <0.05) after cyclosporine treatment. In addition, the metabolic clearance rate of insulin was increased by 25% (p <0.05), and the steady-state insulin clearance rate was increased by 16% (p <0.003). Measurements of insulin sensitivity were unchanged by cyclosporine. These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.

AB - Cyclosporine may have deleterious effects on glucose metabolism. This study was designed to characterize more precisely cyclosporine-induced alterations in glucose homeostasis in a large animal model with hyperglycemic and euglycemic clamp studies in addition to simple bolus glucose (IVGTT) and insulin (IVITT) tolerance tests. In experiment 1, IVGTTs and hyperglycemic clamp studies were performed in eight ewes before and after 4 weeks of cyclosporine treatment. Studies were repeated 4 weeks after cessation of therapy. In experiment 2, IVITTs and euglycemic clamp studies were performed in seven ewes before and after 4 weeks of cyclosporine treatment. Fasting glucose and insulin levels were not affected by cyclosporine treatment. In experiment 1 cyclosporine did not alter IVGTTs; however, during sustained hyperglycemia, cyclosporine caused a 37% decrease in net glucose disposal (p <0.001) and a 39% decrease in plateau plasma insulin levels (p <0.05). In experiment 2 cyclosporine had no effect on IVITTs. Plateau insulin values in euglycemic clamp studies were lowered by 27% (p <0.05) after cyclosporine treatment. In addition, the metabolic clearance rate of insulin was increased by 25% (p <0.05), and the steady-state insulin clearance rate was increased by 16% (p <0.003). Measurements of insulin sensitivity were unchanged by cyclosporine. These experiments suggest that cyclosporine treatment results in impairment of sustained synthesis and secretion of insulin, increased insulin clearance, and unaltered insulin sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0024414503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024414503&partnerID=8YFLogxK

M3 - Article

C2 - 2669194

AN - SCOPUS:0024414503

VL - 106

SP - 163

EP - 170

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -